Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2015

Open Access 01-12-2015 | Erratum

Erratum to: PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells

Authors: Lei Qi, Hidemi Toyoda, Dong-qing Xu, Ye Zhou, Naoto Sakurai, Keishirou Amano, Kentaro Kihira, Hiroki Hori, Eiichi Azuma, Yoshihiro Komada

Published in: Cancer Cell International | Issue 1/2015

Login to get access

Excerpt

Unfortunately, the original version of this article [1] contained an error. After publication it came to the authors’ attention that the figure legends were displayed incorrectly. The correct figure legends can be found below in this erratum. …
Literature
1.
Qi L, Toyoda H, Xu D, Zhou Y, Sakurai N, Amano K, Kihira K, Hori H, Azuma E, Komada Y, et al. PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells. Cancer Cell International. 2015;15:91.PubMedCentralCrossRefPubMed
Metadata
Title
Erratum to: PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells
Authors
Lei Qi
Hidemi Toyoda
Dong-qing Xu
Ye Zhou
Naoto Sakurai
Keishirou Amano
Kentaro Kihira
Hiroki Hori
Eiichi Azuma
Yoshihiro Komada
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2015
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-015-0261-6

Other articles of this Issue 1/2015

Cancer Cell International 1/2015 Go to the issue

Primary research

Analysis of the expression of PHTF1 and related genes in acute lymphoblastic leukemia

Primary research

The dual PI3K/mTOR inhibitor NVP-BEZ235 inhibits proliferation and induces apoptosis of burkitt lymphoma cells

Primary research

Inhibition of miR-191 contributes to radiation-resistance of two lung cancer cell lines by altering autophagy activity

Primary research

RhoGDI2 up-regulates P-glycoprotein expression via Rac1 in gastric cancer cells

Primary research

Cyclin D3 predicts disease-free survival in breast cancer

Primary research

Pathological features of transplanted tumor established by CD133 positive TJ905 glioblastoma stem-like cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits